Roche announced today that the European Commission has approved its innovative drug Mircera to treat anaemia associated with chronic kidney disease (CKD). The approval of Mircera results in a ...

Mircera is an erythropoietin receptor activator with greater activity in vivo as well as increased half-life, in contrast to erythropoietin. It is formulated as a sterile, preservative-free ...

Basel, Switzerland, November 5 (ots/PRNewswire)--Low Haemoglobin Levels Associated With Increased Risk of Cardiovascular Disease and Death Data from the analysis of six major trials for the innovative ...

ZURICH (MarketWatch) -- Roche Holding AG RHHBY plans to launch anemia drug Mircera immediately in the U.K. and Germany and is confident it will win U.S. approval for the drug later this year ...

Mircera has been designed to treat anaemia associated with chronic kidney disease. Mircera is a new long-acting chemically synthesized erythropoiesis-stimulating agent. When approved by the ...

Roche is appealing to a higher power on Mircera. The Swiss drugmaker is appealing a lower court ruling barring U.S. sales of the anemia med, claiming that Mircera doesn't infringe on Amgen's ...

The authors of the ARCTOS study, published in the current issue of the Clinical Journal of the American Society of Nephrology(1), say MIRCERA provides a smooth and steady increase in haemoglobin ...

Amgen Inc. said a federal court granted the biotechnology company a permanent injunction prohibiting Roche Holding AG from selling its Mircera anemia treatment in the U.S., while also upholding a ...

Here's the action so far: A court ruled that Roche's anemia drug Mircera infringes on Amgen's patents on Epogen. But though Young granted Amgen's request for a temporary injunction against Roche's ...

(CN) - The Federal Circuit refused to lift an injunction barring F. Hoffman-La Roche Ltd. from importing its anemia treatment, Mircera, to the United States, saying the drug infringes on some of Amgen ...